Authors
Yuji Oshima, Natsuki Himeno, Takehiko Nakamura, Yoshimasa Ando, Norifumi Takaki, Michika Hirata, Akiko Yamamoto
Published in
Japanese journal of ophthalmology. Oct 15, 2025. Epub Oct 15, 2025.
Abstract
Neovascular age-related macular degeneration (nAMD) can cause vision loss and irreversible blindness. However, its treatment needs to be improved. This study aimed to evaluate the 1-year treatment outcomes in patients with nAMD after switching from 2 mg aflibercept to faricimab.
Retrospective observational study.
We included 83 eyes of 83 patients with nAMD who switched from 2 mg aflibercept to faricimab to extend the administration interval or eliminate exudative changes, with ≥ 1 year of follow-up. We retrospectively examined the 1-year treatment outcomes after switching, with the time of switching as the baseline.
After switching, the mean log minimum angle of resolution best corrected visual acuity was significantly improved from 0.35 to 0.33 (p = 0.0498), and the mean central retinal thickness was significantly reduced from 302 μm to 237 μm (p < 0.0001). A significant reduction was observed in the incidence of subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid (p < 0.05). The mean dosing interval was significantly extended from 5.58 weeks to 9.69 weeks (p < 0.0001). One year after switching, 66 eyes (80%) continued receiving faricimab, while 17 eyes (20%) were switched to other drugs owing to worsening exudation or other reasons.
One year after switching treatment for nAMD from 2 mg aflibercept to faricimab, visual acuity and macular morphology were improved, and the treatment interval was extended. The study's findings could help develop strategies for improving nAMD.
PMID:
41091318
Bibliographic data and abstract were imported from PubMed on 15 Oct 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 37
- Comments 0